Soleno Therapeutics, Inc.SLNONASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank79
3Y CAGR+91.6%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+91.6%/yr
Quarterly compound
Percentile
P79
Within normal range
vs 3Y Ago
7x
Strong expansion
Streak
4 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 21.11% |
| Q3 2025 | 19.53% |
| Q2 2025 | -3.49% |
| Q1 2025 | -21.56% |
| Q4 2024 | -24.18% |
| Q3 2024 | 373.28% |
| Q2 2024 | 22.70% |
| Q1 2024 | 104.64% |
| Q4 2023 | 24.77% |
| Q3 2023 | 4.70% |
| Q2 2023 | 11.04% |
| Q1 2023 | 18.82% |
| Q4 2022 | 3.00% |
| Q3 2022 | -5.47% |
| Q2 2022 | -6.66% |
| Q1 2022 | 1.81% |
| Q4 2021 | -6.18% |
| Q3 2021 | 12.30% |
| Q2 2021 | -17.29% |
| Q1 2021 | 32.34% |
| Q4 2020 | -0.22% |
| Q3 2020 | 0.36% |
| Q2 2020 | 12.23% |
| Q1 2020 | 24.56% |
| Q4 2019 | -0.43% |
| Q3 2019 | -4.72% |
| Q2 2019 | -15.76% |
| Q1 2019 | 47.40% |
| Q4 2018 | -12.39% |
| Q3 2018 | -11.78% |
| Q2 2018 | -5.41% |
| Q1 2018 | 10.84% |
| Q4 2017 | -1.33% |
| Q3 2017 | -22.23% |
| Q2 2017 | 72.56% |
| Q1 2017 | -38.37% |
| Q4 2016 | 18.61% |
| Q3 2016 | -16.59% |
| Q2 2016 | -15.79% |
| Q1 2016 | 12.22% |